A Phase 1b Study of QX1206 in T2DM Patients With NAFLD

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 6, 2025

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2025

Conditions

Type 2 Diabetes Mellitus (T2DM)Non-Alcoholic Fatty Liver Disease (NAFLD)

Interventions

DRUG

QX1206

QX1206 will be administered orally before bedtime

Trial Locations (1)

RECRUITING

Centricity Research Toronto LMC., Toronto

All Listed Sponsors

lead

1Globe Health Institute

INDUSTRY